News
INVO Bioscience Eyes +20 U.S. Cities To Expand Rollout Of Advanced Infertility Treatment ‘INVO Centers’
SAN FRANCISCO, CA / ACCESSWIRE / February 9, 2022 / Today, the global fertility market is a multi-billion industry, yet remains severely underserved, with estimates suggesting more than 90% of couples in need of infertility treatment going without care. INVO...
INVO Bioscience Expands U.S. Commercialization Efforts
Focused on addressing underserved patients within the fertility marketplaceSARASOTA, Fla., Feb. 3, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("Company") ("INVO"), a commercial-stage fertility company focused on expanding access to advanced treatment...
INVO Bioscience Enters into Agreement with Ovoclinic in Spain to Expand INVOcell Commercialization
Agreement follows initial utilization of INVOcell by Ovoclinic phyisicians in early 2021, resulting in successful patient experiences and outcomesOvoclinic will expand use of INVOcell in all four of their clinics and become the Center of Excellence and Training Site...
INVO Bioscience to Participate in the Lytham Partners Winter 2021 Investor Conference
SARASOTA, Fla., Dec. 10, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, announced today that it will be participating in the Lytham Partners...
INVO Bioscience Obtains Regulatory Approval to Commercialize INVOcell In Thailand
INVO's distribution partner, IVF Envimed Company Ltd., set to begin commercialization of the INVOcell system within Thailand.SARASOTA, Fla., Dec. 1, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the...
INVO Bioscience Reports Third Quarter 2021 Financial and Operating Results and Provides Business Update
Company to Host Conference Call Today at 4:30pm ET (Details Below)SARASOTA, Fla., Nov. 15, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a medical device company focused on creating alternative treatments for patients diagnosed...
INVO Bioscience to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ETSARASOTA, Fla., Nov. 9, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Culture...
INVO Bioscience Regains Full U.S. Commercialization Rights
SARASOTA, Fla., Nov. 8, 2021 /PRNewswire/ -- INVO Bioscience, Inc. ("INVO" or the "Company") (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), today announced it will regain full U.S. commercialization...
INVO Bioscience Announces Four Individual Poster Abstracts Discussing the Benefits of INVOcell Presented at the 2021 American Society for Reproductive Medicine (ASRM) Congress & Expo
SARASOTA, Fla. and BALTIMORE, Oct. 20, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for...
INVO Bioscience Announces Grand Opening of “Positib Fertility, an INVO Center” in Monterrey, Mexico on November 1, 2021
Positib Fertility, an INVO Center, becomes first international JV-owned clinic focused on providing INVOcell to assist the underserved patients in need of advanced fertility careSARASOTA, Fla. and MONTERREY, Mexico, Oct. 14, 2021 /PRNewswire/ -- INVO Bioscience, Inc....